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ORIGINAL PAPER
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ABSTRACT
Objectives: In Belgium, eleven AIDS Reference Centers (ARCs) and seven AIDS Reference 
Laboratories diagnose and treat HIV-positive individuals and track patients under care. As AIDS-
related deaths are avoided and the HIV-positive population ages, non-infectious comorbidities 
(NICMs), such as cardiovascular disease, renal disease and certain cancers, play a larger role in the 
quality and length of patients’ lives. This study aims to characterize the HIV-positive population 
in Belgium in terms of the prevalence of key NICMs.
Methods: We performed a retrospective study of 5787 HIV-positive patients under follow-up at 
four ARCs across Belgium between 1st of June 2014 and 1st of July 2016.
Results: The mean age of patients under follow-up was 46.7 (SD = 11.6) years, and the mean 
nadir CD4 count was 268.8  cells/mm3 (SD  =  189.5). The prevalence of diabetes mellitus, 
arterial hypertension and chronic kidney disease (CKD) were 5.9, 31 and 7.8%, respectively. 
Cardiovascular events, defined as the occurrence of myocardial infarction, stroke or an invasive 
coronary procedure, occurred in 2.9% of patients. The highest age-adjusted mortality rates were 
observed among patients 51–55 years of age. Mortality rates were also higher among patients 
with CKD and patients with viremic hepatitis C virus (p < 0.05).
Conclusions: Helping the aging HIV-positive population avoids premature morbidity and 
mortality from NICMs represents a key challenge to further improve patient outcomes. 
Belgium has an advanced system of HIV care and patient management; however, standardized 
data collection across ARCs is needed to improve knowledge sharing and to support future 
countrywide analyses.
Introduction
The HIV epidemic has been transformed from an almost 
universally lethal viral disease to a chronic disease with 
near normal life expectancy, particularly in high-income 
countries [1–3]. In Belgium, a robust system of HIV 
patient tracking and care has been developed through 
the establishment of eleven AIDS reference centers 
(ARCs) and seven reference laboratories. A national 
analysis of the continuum of HIV care in Belgium from 
2006 to 2008 found that 98.2% of diagnosed HIV indi-
viduals were linked to care and 90.8% were retained in 
HIV care [4]. In 2015, there were 15,266 HIV-infected 
patients under care at the 11 ARCs, with 2.7 new cases 
diagnosed per day [5].
As AIDS-related mortality has significantly declined 
through careful patient management and universal 
access to combination antiretroviral therapies (cART), 
physicians must consider the healthcare needs of the 
aging HIV-infected population. Multiple reviews of 
HIV-infected and healthy populations in high-income 
countries found that the mortality risk for aging HIV-
infected patients with controlled viral load and CD4 
counts greater than 500 is not necessarily higher than 
that of the general population [6,7]; however, there is evi-
dence that HIV-infected patients may have a higher risk 
of developing non-infectious comorbidities (NICMs), 
including cardiovascular disease and kidney disease at 
a younger age than an age-matched uninfected popula-
tion [3]. In a cross-sectional retrospective case–control 
study in Italy, there was a significantly greater NICM 
risk among HIV-infected patients than among matched 
controls. Additionally, the prevalence of NICMs among 
patients aged 41–50 years was similar to controls aged 
51–60 years [8]. Age, sex, nadir CD4 count and ART 
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exposure were independent predictors of polypathology, 
or the simultaneous prevalence of two or more NICMs 
[8].
In recent years, the ARCs in Belgium have collected 
cohort data on patients under care. In this article, we 
synthesize the epidemiological data from four of these 
reference centers and present prevalence estimates of 
diabetes mellitus (DM), arterial hypertension (AT), car-
diovascular events (CE), chronic kidney disease (CKD), 
anal cancer (AC), Hodgkin’s Lymphoma (HL), lung can-
cer and liver cancer in the Belgian HIV-infected pop-
ulation. Additionally, mortality rates by age group are 
presented, as well as the prevalence rates of key NICMs 




St. Pierre University Hospital, Brussels, Liège University 
Hospital, Ghent University Hospital, and Erasme 
University Hospital, Brussels, agreed to participate 
in the study. These centers provide care for approxi-
mately 40% of the HIV-positive patients in the coun-
try. Patients were included in the study if they received 
follow-up care at least once between 1 June 2014 and 1 
July 2016. All patients under follow-up were assigned 
unique identification numbers to protect confidenti-
ality and were included in the analysis. The study was 
approved separately by the ethical committees at all 
four centers.
Definitions of NICMs
The prevalence rates of NICMs in the living patient pop-
ulation under follow-up between 1 June 2014 and 1 July 
2016 were determined using definitions based on the 
literature and constrained by available data.
CKD was defined as a confirmed estimated glomer-
ular filtration rate (eGFR) <60  mL/min/1.73  m2 for 
patients with eGFR  >60  mL/min/1.73  m2 at baseline, 
or a confirmed 25% decline in eGFR for patients with 
eGFR <60 mL/min/1.73 m2 at baseline [9].
CE was defined as the occurrence of myocardial 
infarction (MI), cerebrovascular accident, or invasive 
cardiovascular procedure (coronary artery bypass graft-
ing, stenting). DM was defined as the clinical diagno-
sis of the condition or the prescription of antidiabetic 
drugs or insulin. Similarly, AT was defined as the clinical 
diagnosis of AT or the prescription of antihypertensive 
medication. HL, AC, lung cancer and liver cancer were 
determined by a diagnosis.
Polypathology was defined as concomitant diagno-
sis of more than one of the NICMs considered in this 
study (DM, CE, CKD, AT, HL, AC, lung cancer and liver 
cancer).
Statistical analysis
Analyses were performed with R Statistical Software 
version 3.2.2 [10].
Only deaths that occurred between 1 June 2014, and 1 
July 2016 were considered in the mortality calculations. 
Deaths from any cause were included. Age-adjusted 
mortality rates were calculated using the combined 
population and deaths in each five-year age group of 
the four centers.
The relationship between categorical variables was 
assessed using Fisher’s exact test and odds ratios. A 
p-value < 0.05 was considered significant.
Results
There were 5787 living patients under regular care in the 
four AIDS References Centers which were included in 
this study, of which 37.6% were female. Mean age was 
46.7 years (SD = 11.6 years) and almost 40% of the popu-
lation was over the age of 50; 47.1% were from European 
origin, 42.4% were from sub-Saharan Africa, and 3.1% 
were from Latin America and the Caribbean (Table 1).
Treatment rates were high, with 95.3% of patients 
under follow-up on cART. The most recent CD4 count 
during follow-up was an average of 566.2 cells/mm3 
(SD = 280.1). Reflecting the high treatment rates in the 
centers, 57.1% of patients had a recent CD4 count above 
500 cells/mm3, while 21.4% had a count between 350 and 
499, 14.1% between 200 and 349, and 8.3% under 200.
Patients had an average nadir CD4 count of 268.8 
cells/mm3 (SD = 189.5). The proportion of patients with 
Table 1. Patient characteristics in four AIDS reference centers 
(ARCs) in Belgium, 2014–2016.
aOnly includes patients with known treatment status (n = 4880, 84.3% of 
sample).
bOnly includes patients with known nadir CD4 (n = 4880, 84.3% of sample).




Mean age 46.7 11.6
Male gender 3609 (62.4%)
On treatmenta 4648 (95.3%)
Region of origin
Europe 2726 (47.1%)
Sub-Saharan Africa 2452 (42.4%)




Mean recent CD4 (cells/mm3) 566.2 280.1
 <200 454 (8.3%)
 200–349 772 (14.1%)
 350–499 1173 (21.4%)
 500+ 3126 (57.1%)
Mean nadir CD4 (cells/mm3)b 268.8 189.5 
 <200 1740 (39.0%)
 200–349 1528 (34.3%)
 350–499 722 (16.2%)
 500+ 470 (10.5%)
Other risk factors
Smoking (former or current)c 1849 (39.9%)
Hepatitis C RNA positive 164 (2.8%)
52   J. GUNTER ET AL.
a nadir CD4 count below 200 cells/mm3 was 39.0%, and 
the proportion between 200 and 350 was 34.3%. The 
remaining 26.7% of patients had a nadir CD4 count 
above 350. To consider other risk factors, just under 
40% of patients with known smoking status (n = 4636, 
80.1% of sample) were current or former smokers, and 
2.8% were chronically coinfected with hepatitis C virus 
(HCV) (Table 1).
Prevalence of NICMs
Prevalence rates by age group are listed in Table 2. 
Prevalence rates of key NICMs increased by age group, 
with a steep increase in the 51–60-year age group and the 
over 60 age group. The prevalence rates of HL and AC were 
higher in the 51–60-year olds than in patients older than 60. 
Of note, almost 11% of patients 51–60 years old and 25% of 
patients 60 and older had CKD. Similarly, the prevalence of 
CE jumped from 1.3% in the 41–50-year-old age group to 
5.1% in 51–60 years and 8.0% in patients 60 and older. Rates 
of polypathology reached 24.5% in the over 60 age group.
Mortality
Mortality rates were calculated by age group. Overall, 
there were 31 deaths during the study period. Of these, 
32% occurred in patients aged 51–55, for whom the 
age-adjusted mortality rate was 12 deaths per 1000 
patients. The group with the second highest mortality 
rate was in patients aged 26–30, with a rate of 9 deaths 
per 1000 patients.
The prevalence estimates in living patients and 
patients who died during the study inclusion period 
with a diagnosis of at least one NICM were compared 
(Table  3). In the deceased patient population, the 
prevalence of CKD was 22.6%, while the prevalence 
of CE was 12%. Patients with CKD had 3.5 (95% CI: 
1.2–8.3) times the risk of death during the study period 
compared to patients without CKD (p  <  0.05). There 
was no significant difference in risk of death between 
patients who had been diagnosed with DM, AT or CE. 
Anal cancer, lung cancer, liver cancer and HL were not 
considered due to the small number of cases in both liv-
ing and deceased patients. HCV-RNA-positive patients 
had 6.6 (95% CI: 2.0–17.7) times the risk of death during 
the study period than patients without HCV.
Discussion
This cross-sectional, retrospective analysis of cohort 
data from four Belgian HIV reference centers pro-
vides a summary of patient characteristics and mor-
tality risk factors. Additionally, this study represents 
the first multicenter analysis in Belgium that provides 
age-stratified prevalence rates of key NICMs in the 
aging HIV-positive population. Almost 40% of the 
infected population in the four centers was 50 years or 
older in 2015. The prevalence rates of CKD, DM, AC 
and HL were the highest in the 51–60-year-old popu-
lation, and most deaths occurred among patients aged 
51–55. Prevalence and the advancement of NICMs may 
continue to rise as the HIV-positive population ages. 
Furthermore, the significantly higher risk of mortal-
ity among patients coinfected with HCV, though not 
unexpected, underscores the importance of access to 
antiviral therapies for HCV for eligible patients when 
possible. These findings highlight a need for prudent 
patient management to avoid premature morbidity and 
mortality from NICMs in addition to the management 
of patients’ antiretroviral regimens.
Table 2. Prevalence of non-infectious comorbidities (NICMs) in four AIDS reference centers (ARCs) in Belgium, 2014–2016.
aOnly includes patients for whom data on CE was available (n = 4880, 84% of sample).
NICM All ages (n = 5787) (%)
≤40 years (n = 1833) 
(%)
41–50 years 
(n = 1824) (%)
51–60 years 
(n = 1433) (%)
>60 years (n = 695) 
(%)
Diabetes mellitus 5.9 1.8 4.5 10.1 12.2
Arterial hypertension 31.0 16.5 30.2 43.7 45.2
Cardiovascular eventsa 2.9 0.6 1.3 5.1 8.0
Chronic kidney disease 7.8 1.8 5.2 10.6 24.8
Anal cancer 0.3 0.2 0.2 0.7 0.4
Hodgkin’s lymphoma 0.5 0.2 0.4 0.9 0.6
Lung cancer 0.1 0 0.1 0.3 0
Liver cancer 0.1 0 0 0.1 0.1
Polypathology 8.9 2.1 5.3 14.6 24.5
Table 3. Differences in mortality among patients with or without DM, CE, CKD, HCV, or polypathology 2014–2016.
aOnly includes patients for whom data on CE was available (n = 4880, 84% of sample).
**indicates significance at the p < 0.05 level.
NICM or risk factor Prevalence – living patients (n = 5787) (%)
Prevalence – deceased patients 
(n = 31) (%) OR 95% CI p value
Diabetes mellitus 5.9 12.9 2.3 0.6–6.8 0.1110
Arterial hypertension 31.0 16.1 0.4 0.1–1.1 0.0811
Cardiovascular eventsa 2.9 8.0 2.9 0.3–11.9 0.1660
Chronic kidney disease 7.7 22.6 3.5 1.3–8.4 0.0085**
Hepatitis C virus 2.8 16.1 6.6 2.0–17.7 0.0018**
Polypathology 8.9 19.4 2.5 0.8–6.2 0.0541
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Almost 40% of patients had a nadir CD4 count under 
200 cells/mm3, potentially putting them at greater risk 
for the development of NICMs. There is evidence that 
low nadir CD4 counts and declining CD4 counts are 
associated with a greater risk of some NICMs and death 
[11,12]. Strategies to improve testing among high-risk 
groups in Belgium are needed to reduce the number of 
late presenters, or patients who have a CD4 count of 
less than 350 cells/mm3 at diagnosis [13]. In addition 
to the integration of comorbidity prevention and mon-
itoring into the standard of care for patients, improv-
ing rates of early diagnosis and cART initiation may 
lower the incidence of NICMs among the HIV-positive 
population.
There were some limitations due to the historical 
data that were collected in each of the four centers. One 
of the major takeaways from the analysis was the need 
for standardized definitions of risk factors and comor-
bidities to strengthen data collection in the ARCs. For 
example, the definition of CE as MI, cerebrovascular 
accident, or invasive cardiovascular procedure (coronary 
artery bypass grafting, stenting) did not include fatal MI 
or fatal stroke because patients’ causes of death were not 
systemically recorded in all centers. This could explain 
the lack of significant association between CE and death 
in this analysis. The definition of CKD, though originally 
from a published study, may be an overestimation of the 
condition due to the inhibition of creatinine excretion, 
and therefore, artificial increase in creatinine blood lev-
els, induced by certain widely used medications in the 
treatment of HIV, diabetes and hypertension.
Additionally, the recording of tobacco use and body 
mass index was not consistent between centers. The 
prevalence of tobacco smoking or historical smoking 
was measured through self-reported rates of smok-
ing. Data on cessation rates for patients who have ever 
smoked were not available in all centers; thus, a positive 
response indicates that the patient has previously been 
or still is a smoker. These data may underestimate the 
rates of smoking in the population due to underreport-
ing by either the patient or practicing physician. Despite 
possible underreporting, almost half of the patients were 
past or present smokers, which may contribute to the 
development of NICMs among patients.
In conclusion, Belgium has an advanced system of 
HIV patient care and tracking in place in 11 ARCs across 
the country. However, this study represents the first mul-
ticenter data analysis focusing on the prevalence rates of 
key NICMs and risk factors in the HIV-positive popula-
tion. This study highlights the need for standardized data 
collection to allow uniform risk factor and NICM defini-
tions at the national level to make countrywide analyses 
possible. The data collection methodology used in this 
study could be expanded to include all eleven reference 
centers and used to initiate prospective surveillance as 
the foundation for predictive modeling efforts to address 
NICMs in the HIV-positive population.
